Researchers have developed a novel gene therapy approach targeting heart regeneration post-myocardial infarction by leveraging the NPPA gene to enhance the production of atrial natriuretic peptide (ANP). This innovative strategy utilizes RNA-lipid nanoparticles to transfect muscle cells, enabling them to produce a pro-ANP molecule that circulates in the bloodstream until it reaches the heart, where it is activated by the enzyme Corin. This method circumvents the challenges associated with direct cardiac drug delivery, which has historically hindered effective treatment options.

The significance of this work lies in its potential to restore heart function and reduce scarring after heart attacks. ANP is known to promote angiogenesis, mitigate inflammation, and limit fibrosis, but its clinical application has been constrained due to its rapid degradation. By generating ANP within the heart from a prodrug synthesized in skeletal muscle, this approach not only enhances the therapeutic window of ANP but also capitalizes on the heart’s unique enzymatic environment, where Corin is abundant. In preclinical studies, a single injection of this gene therapy markedly improved cardiac function and diminished scar formation in both small and large animal models.

The implications of this research are profound for the field of cardiac regenerative medicine. This strategy could shift the paradigm of how we approach drug delivery to the heart, emphasizing the use of prodrugs and leveraging the body’s own mechanisms for activation. As a result, this could accelerate the development of gene therapies for various cardiac conditions, potentially leading to more effective treatments that enhance healthspan and recovery in aging populations at risk for heart disease.

Source: fightaging.org